Biodesix price target lowered to $1.50 from $3 at Craig-Hallum

Craig-Hallum lowered the firm’s price target on Biodesix (BDSX) to $1.50 from $3 and keeps a Buy rating on the shares. The firm believes Biodesix is likely to sell off even further on a Q1 volume and revenue miss and lowered guidance. The company cites disruption from a sales force reorganization. Craig-Hallum expects it will take a few quarters for the company to get back on the right track, and thus has revised its estimates below the low end of the new guidance range.